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Background: Tuberculosis (TB) mortality remains high across sub-Saharan Africa despite integration of TB and
HIV/ART programmes. To inform programme design and service delivery, we estimated mortality by time from
starting TB treatment.
Methods: Routinely collected data on TB treatment, vital status, and the timing and causes of death, were linked to
cardio-respiratory autopsy data, from 1995–2008, from a cohort of male platinum miners in South Africa. Records were
expanded into person-months at risk (pm).
Results: 4162 TB episodes were registered; 3170 men were treated for the first time and 833 men underwent
retreatment. Overall, 509 men died, with a case fatality of 12.2% and mortality rate of 2.0/100 pm. Mortality was
highest in the first month after starting TB treatment for first (2.3/100 pm) and retreatment episodes (4.8/100 pm).
When stratified by HIV status, case fatality was higher in HIV positive men not on ART (first episode 14.0%; retreatment
episode 26.2%) and those on ART (12.0%; 22.0%) than men of negative or unknown HIV status (2.6%; 3.6%). Mortality
was also highest in the first month for each of these groups. Mortality risk factors included older age, previous TB, HIV,
pulmonary TB, and diagnostic uncertainty. The proportion of deaths attributable to TB was consistently overestimated
in clinical records versus cardio-respiratory autopsy.
Conclusions: Programme mortality was highest in those with HIV and during the first month of TB treatment in all
groups, and many deaths were not caused by TB. Resource allocation should prioritise TB prevention and accurate
earlier diagnosis, recognise the role of HIV, and ensure effective clinical care in the early stages of TB treatment.
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In South Africa, tuberculosis (TB) is the most commonly
reported cause of death in adults, and most TB-deaths
are associated with HIV-infection [1,2]. Despite dedicated
TB programmes and their integration with HIV pro-
grammes as antiretroviral treatment (ART) is increasingly
available across sub-Saharan Africa (SSA), mortality
within TB programmes remains high in many settings
[2-6]. Detailed understanding of the timing and causes
of mortality provides a focus for the planning of services
and interventions.
TB mortality tends to be highest in the first two
months on TB treatment [7-11], and early mortality is* Correspondence: nigel.field@ucl.ac.uk
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unless otherwise stated.increased in specific patient-groups, including older people
and those with previous TB episodes, smear-negative TB
and extra-pulmonary TB [9]. HIV co-infection increases
the TB mortality rate, and HIV positive patients continue
to die throughout TB treatment, whereas mortality in HIV
negative patients declines rapidly after the first month of
treatment [5,7,12-15]. While ART improves outcomes for
HIV-positive TB patients overall, the mortality rate during
the first one to two months of TB treatment for HIV-
infected patient groups seems not to be reduced by
ART [11,16]. This could reflect selection of those most
immunocompromised for ART or the impact of im-
mune reconstitution inflammatory syndrome (IRIS) on
survival [11,16].
Only two studies describing the cause of death in TB
patients by time on treatment have verified cause of
death using autopsy, both prior to the introduction ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stages of treatment are attributable to TB, whereas those
in the later stages of treatment usually have other causes
[4,5,14,17-19]. The cause of death also differs by HIV sta-
tus in TB programmes, with most deaths in HIV negative
patients attributable to TB, whereas HIV positive patients
die from a variety of infectious causes [5,18].
However, the available data are limited by relatively
small patient numbers, and no single study has investi-
gated the timing and causes of deaths among first and
re-treatment episodes while stratifying by HIV status
and whether patients have received ART. Furthermore,
although we know that clinical misclassification of
deaths in TB programmes is common [16,20,21], there
is a paucity of studies using autopsy to confirm the
cause of death [22,23].
We have previously reported data from a South African
platinum mining company, following a well-defined popu-
lation with a high burden of TB (1,866 per 100,000 person
years between 1995–2008) and HIV to show the impact of
HIV, ART and TB on population mortality [3], and have
described measurement errors in estimating TB-specific
mortality [21]. Here, we focus on mortality at a programme
level by time from starting TB treatment in a large cohort,
including patients on ART and using multiple data sources
to determine the timing and cause of death with a high
degree of precision.
Methods
The study setting was the TB treatment programme of a
platinum mine in North West Province, South Africa.
Medical care is provided free of charge by the company
and includes primary care, hospital facilities, and an HIV
programme providing ART since April 2003 [24]. Miners
diagnosed with TB received treatment in accordance
with South African National TB guidelines at the time,
which recommended regimen 1 for new adult TB pa-
tients (comprising two months of rifampicin (R), iso-
niazid (H), pyrazinamide (Z), ethambutol (E), followed
by four months of RH) and regimen 2 for retreatment
cases (comprising two months of RHZE and strepto-
mycin, one month of RHZE, and five months of RHE)
[25]. HIV-positive employees are registered on the
ART programme, which monitors CD4 counts, clinical
status and, where appropriate, the mining company
provides free ART. Patients were eligible for ART with
a CD4 count of <250 cells/μl, WHO stage 4, or WHO
stage 3 with a CD4 count of <350 cells/μl. All semi-
skilled and unskilled male miners registered on the TB
programme were selected for this study because it was
possible to link these individuals across TB programme,
HIV/ART programme, death register, autopsy register,
and company databases using unique employee identifica-
tion codes.Routine TB-programme data were available for TB
episodes with treatment initiated between 1 January
1995 and 31 December 2008. We included all diagnosed
TB episodes, regardless of site of TB (pulmonary, extra-
pulmonary, or unknown) and of bacteriological confirm-
ation, to assess overall mortality at a programme level.
Sputum smear and culture data were only available after
2000, and other clinical data, including antibiotic re-
sistance, were unavailable. We classified TB cases as
“confirmed” if at least one sputum culture was positive
for Mycobacterium tuberculosis, “probable” if at least
one sputum smear was positive for acid-fast bacilli,
and “possible” if there was at least one negative sputum
culture and/or sputum smear. The remaining cases lacked
microbiological data and were treated as a separate “no
data” category. TB episodes were classified as first episode
unless previous episodes were documented during the
study period or recorded in the programme database.
Men were classified as HIV positive if they had a recorded
HIV positive test; if they were identified as HIV positive
through the TB or ART programme databases; if their
medical record or death certificate stated HIV, AIDS or a
euphemistic term such as ‘immune compromised’; or if
their cause of death was obviously an AIDS-related condi-
tion (Pneumocystis jirovecii pneumonia (PCP), aspergillus,
nocardia pneumonia, cryptococcal disease, oesophageal
candidiasis, lymphadenopathy, lymphocytic interstitial
pneumonitis, cytomegalovirus pneumonia, toxoplasmo-
sis, or Kaposi’s sarcoma) [3]. HIV testing dates and HIV
status at death were not routinely recorded, and HIV
negative results only rarely recorded, so men not known
to be positive were classified as ‘HIV negative or un-
known’. 97 men (6 originally classed as HIV negative and
91 as HIV status unknown) were reclassified as HIV posi-
tive because their cause of death was clearly AIDS-related.
Men were classified as being on ART if this was recorded
by TB or ART programme databases. CD4 counts, HIV
viral load and disease stage were not available for most
men in the cohort.
The timing and cause of death were the primary out-
comes. Men entered the cohort on the day of initiating
TB treatment and remained in the cohort for six months
after this date for first TB episodes and for eight months
for retreatment episodes, and were otherwise censored
only when they died within these time periods. Our ra-
tionale here was to understand overall programme mortal-
ity during the standard periods of treatment, when most
deaths occur. We know that data on hospital transfer and
treatment default were incomplete and susceptible to mis-
classification, but timing of death is extremely reliable in
this study due to the short follow-up time, and availability
of multiple data sources used to ascertain date of death.
These included the hospital death register, personnel re-
cords, ART and TB programme records, and the provident
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poses for twelve months after men leave the mine). Autop-
sies of cardio-respiratory organs were conducted on miners
for compensation purposes, with the consent of next of kin,
and regardless of the clinical cause of death. The lungs are
removed at the place of death, placed in formalin and sent
to the National Institute for Occupational Health (NIOH)
in Johannesburg where they are examined macroscopically
and histologically according to a standard protocol by ana-
tomical pathologists with experience in lung pathology. At
least six tissue sections from the upper, middle and lower
zones of both the right and left lungs, as well as sections
of one main bronchus and two hilar lymph nodes are rou-
tinely processed for histology. Where there is any clinical
or pathological evidence of infection, tissue sections are
stained with alcian-blue (for cryptococcus), Ziehl-Neelsen
(for mycobacteria) and Grocott (for Pneumocystis and
other fungi), in addition to haematoxylin and eosin. Infec-
tions are diagnosed according to standard histological cri-
teria [26]. Briefly, bacterial pneumonia is defined as the
presence of consolidation with polymorphonuclear leuko-
cytes in alveolar spaces, in the absence of positive stains
for mycobacteria, fungi, pneumocystis, cryptococci, nocar-
dia or other organisms. Tuberculosis is diagnosed 1) in
the presence of granulomatous inflammation with positive
Ziehl-Neelsen stains or 2) in the presence of granuloma-
tous inflammation, other causes having been excluded by
special stains and 3) cognisance is taken of atypical reac-
tions to mycobacteria which may occur in immune-
compromised patients such as poorly formed granulomas,
sarcoidal-like granulomas, bland necrosis and neutrophil
rich exudates. We compared the clinical cause of death to
cardio-respiratory autopsy data obtained from the NIOH
autopsy database.
Case fatality was calculated for each time period, and
records were expanded into person months at risk (pm),
by time from starting TB treatment, to calculate mortal-
ity rates per 100 pm with 95% CI. Incidence rate ratios
(IRR) were used to quantify differences in mortality rates
with 95% CI, using Poisson regression. Risk factors for
dying were identified using Poisson regression, separ-
ately for the first month of treatment and later months
in univariable and multivariable analyses, with age and
HIV/ART status as time-varying covariates. Chi-squared
tests were used to compare characteristics of those aut-
opsied and those not. Kaplan-Meier survival analysis was
used to generate survival curves and a log rank test was
used to compare survival between groups. All analyses
were conducted using Stata 11 (Stata Corp, College
Station, TX, USA).
Ethical approval was obtained from the Human Research
Ethics Committee (Medical) of the University of the
Witwatersrand, South Africa (M041028), and the UCL
Research Ethics Committee, United Kingdom (1641/001).The Committees specifically addressed issues of consent
and confidentiality. Given the retrospective nature of the
study; high mortality; use of routine databases linked by a
unique number; and removal of personal identifiers prior
to analysis, specific written consent for inclusion in this
research was not required. Autopsies were conducted with
written consent from the next of kin, in accordance with
the South African Occupational Diseases in Mines and
Works Act. The project is covered by the UCL Data Pro-
tection Registration (Reference No Z6364106/2008/8/18,
Section 19, Research: Health Research).
Results
During 1995 to 2008, there were 4162 treated TB epi-
sodes recorded by the mine hospital TB programme.
Table 1 shows that the majority were in employment for
at least ten years, aged 35–54 years at first episode, and
diagnosed with pulmonary TB. 3170 men had a first epi-
sode of TB, of whom 2046 (65%) were HIV positive.
There were 992 retreatment episodes in 833 men, of
which 775 episodes (78%) were in HIV positive men.
Overall, 509 men died, with a case fatality of 12.2%
and mortality rate of 2.0/100 pm (Table 2). Mortality
was highest in the first month of treatment for both first
(2.3/100 pm) and retreatment TB episodes (4.8/100 pm).
First episode mortality rates were lower than retreatment
mortality rates at each comparable month. By the end of
the sixth month after starting TB treatment, the cumula-
tive case fatality was 9.7% for first episodes and 17.6% for
retreatment episodes. The mortality rate remained stable
from the second month for first TB episodes, whereas the
mortality rate declined throughout retreatment.
Among first TB episodes (Table 3), case fatality was
lower in men with negative or unknown HIV status
(2.6%) than HIV positive men on ART (12.0%) and HIV
positive men not on ART (14.0%). In each group, mor-
tality was highest in the first month of treatment, and
decreased later, although not to the same extent in all
groups. Within the group on ART, overall mortality was
2.1/100 pm, and was not significantly different to the
group not on ART (2.5/100 pm). There was also no sig-
nificant difference in mortality between the 208 men who
started ART within one month of starting TB treatment
(2.0/100 pm (1.3-2.9)) and the 167 men who were treated
with ART for longer than one month when starting TB
treatment (2.4/100 pm (1.6-3.6)).
Mortality by month in HIV positive men, whether or
not on ART, was considerably higher during retreatment
than during first TB episodes, whereas monthly mortality
in men who were HIV negative or of unknown status was
similar during first and retreatment episodes (Tables 3
and 4). Nevertheless, the overall trends in monthly case
fatality and mortality rates by HIV status among men
undergoing TB retreatment were similar to the trends we
Table 1 Patient characteristics for 4,162 TB episodes occurring between 1995 and 2008
First episode n (%) Retreatment episode n (%)
TOTAL 3170 992
Age at diagnosis <35 years 438 (14) 86 (9)
35-44 years 1208 (38) 364 (37)
45-54 years 1261 (40) 470 (47)
>54 years 263 (8) 72 (7)
Treatment sequence First episode 3170 (100)
Second episode 833 (84)
Third episode 140 (14)
Fourth or fifth episode 19 (2)
Time in employment at diagnosis <1 year 237 (7) 27 (3)
1- < 5 years 526 (17) 116 (12)
5- < 10 years 461 (15) 149 (15)
10+ years 1946 (61) 700 (71)
Year diagnosed 1995-1998 509 (16) 234 (24)
1999-2002 848 (27) 330 (33)
2003-2005 908 (29) 290 (29)
2006-2008 905 (29) 138 (14)
HIV/ART status Negative/unknown 1124 (36) 217 (22)
Positive: ART 375 (12) 277 (28)
Positive: no ART 1671 (53) 498 (50)
TB site Pulmonary 1706 (54) 687 (69)
Extra-pulmonary1 1276 (40) 259 (26)
No data 188 (6) 46 (5)
Certainty of diagnosis2 Confirmed 740 (23) 269 (27)
Probable 760 (24) 314 (32)
Possible 856 (27) 264 (27)
No data 814 (26) 145 (15)
Outcome Cured/Completed 2362 (75) 589 (59)
Failed 54 (2) 25 (3)
Did not complete 170 (5) 41 (4)
Transferred 276 (9) 136 (14)
Died 308 (10) 201 (20)
Autopsy data available Alive 2862 (90) 791 (80)
Died – Cardiorespiratory autopsy 180 (6) 113 (11)
Died – No autopsy 128 (4) 88 (9)
1Extra-pulmonary cases were in the following sites: 59 lymph node, 489 pleural, 21 meningitis, 65 bone/joint, 124 other organs, 77 miliary.
2TB cases were classified as “confirmed” if at least one sputum culture was positive for Mycobacterium tuberculosis, “probable” if at least one sputum smear was
positive for acid-fast bacilli, and “possible” if there was at least one negative sputum culture and/or sputum smear. The remaining cases lacked microbiological
data and were treated as a separate “no data” category.
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the first month of treatment for all groups. Kaplan-Meier
curves show differences in survival by first and retreat-
ment episodes and according to HIV status (log rank test
p < 0.01) (Figure 1).
We analysed risk factors associated with death for first
and later months of treatment (Table 5). For both timeperiods, in univariable analysis, mortality was associated
with older age, previous TB, HIV infection, pulmonary
TB, and certainty of diagnosis. Mortality was higher in
more recent calendar periods in the first month of
treatment, but not in later months. Compared to the
unadjusted models, the findings were similar in multi-
variable analyses. The exception was that we observed
Table 2 Case fatality, mortality rate and risk of death by month since starting TB treatment, by first and retreatment
TB episodes
Time on
treatment
n Number of
deaths
Cumulative case
fatality (%)
Person
months
Rate per 100 pm
(95% CI)
IRR
(95% CI)
p-value
First episode 1st month 3170 71 2.2 3132 2.3 (1.8-2.9) 1.0
2nd month 3099 50 3.8 3072 1.6 (1.2-2.1) 0.72 (0.50-1.0) 0.07
3rd month 3049 47 5.3 3023 1.6 (1.2-2.1) 0.69 (0.47-0.99) 0.05
4th month 3002 46 6.8 2979 1.5 (1.2-2.1) 0.68 (0.47-0.99) 0.04
5th month 2956 44 8.1 2936 1.5 (1.1-2.0) 0.66 (0.45-0.96) 0.03
6th month 2912 50 9.7 2889 1.7 (1.3-2.3) 0.76 (0.53-1.10) 0.14
Overall 3170 308 9.7 18030 1.7 (1.5-1.9)
Retreatment episode 1st month 992 46 4.6 967 4.8 (3.6-6.4) 1.0
2nd month 946 28 7.5 933 3.0 (2.1-4.3) 0.63 (0.39-1.01) 0.05
3rd month 918 34 10.9 898 3.8 (2.7-5.3) 0.80 (0.51-1.24) 0.31
4th month 884 32 14.1 865 3.7 (2.6-5.2) 0.78 (0.50-1.22) 0.28
5th month 852 19 16.0 844 2.3 (1.4-3.5) 0.47 (0.28-0.81) 0.01
6th month 833 16 17.6 827 1.9 (1.2-3.2) 0.41 (0.23-0.72) <0.01
7th month 817 17 19.4 808 2.1 (1.3-3.4) 0.44 (0.25-0.77) <0.01
8th month 800 9 20.3 793 1.1 (0.6-2.2) 0.24 (0.12-0.49) <0.01
Overall 992 201 20.3 6935 2.9 (2.5-3.3)
Overall 4162 509 12.2 24965 2.0 (1.9-2.2)
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having no smear or culture data in the adjusted model,
and we found this was due to the confounding effect of
year of diagnosis. A strong effect of calendar period
remained in the multivariable model.3 For HIV positiveTable 3 Case fatality, mortality rate and risk of death by mon
HIV status
HIV/ART status Time on
treatment1
n Number
of deaths
Cumulat
fatality (%
HIV negative or unknown 1st month 1124 10 0.9
2nd month 1114 8 1.6
3rd-6th month 1106 11 2.6
Overall 1124 29 2.6
HIV positive on ART 1st month 375 15 4.0
2nd month 360 2 4.5
3rd-6th month 358 28 12.0
Overall 375 45 12.0
HIV positive not on ART 1st month 1671 46 2.8
2nd month 1625 40 5.1
3rd-6th month 1585 148 14.0
Overall 1671 234 14.0
1Months 3–6 were grouped because mortality rates were observed to be stable in n
were small.men on ART compared to those not on ART, the adjusted
IRR was lower in the first month (IRR 0.86 (0.55-1.36))
and in subsequent months (IRR 0.77, 0.58-1.01), although
not significantly so. Kaplan-Meier curves show survival by
certainty of TB diagnosis, excluding episodes withoutth since starting TB treatment for first TB episodes, by
ive case
)
Person
months
Rate per 100 pm
(95% CI)
IRR
(95% CI)
p-value for
trend
<0.01
1117 0.9 (0.5-1.7) 1.0
1109 0.7 (0.4-1.4) 0.81 (0.32-2.04)
4401 0.2 (0.1-0.5) 0.28 (0.12-0.66)
6627 0.4 (0.3-0.7)
0.98
367 4.1 (2.5-6.8) 1.0
358 0.6 (0.1-2.2) 0.14 (0.03-0.60)
1372 2.0 (1.4-3.0) 0.50 (0.27-0.94)
2097 2.1 (1.6-2.9)
0.22
1647 2.8 (2.1-3.7) 1.0
1604 2.5 (1.8-3.4) 0.89 (0.58-1.36)
6054 2.4 (2.1-2.9) 0.88 (0.63-1.22)
9306 2.5 (2.2-2.9)
ew TB episodes during this time period and the numbers of deaths
Table 4 Case fatality, mortality rate and risk of death by month since starting TB treatment for retreatment TB
episodes, by HIV status
HIV/ART status Time on
treatment1
n Number
of deaths
Cumulative case
fatality (%)
Person
months
Rate per 100 pm
(95% CI)
IRR
(95% CI)
p-value for
trend
0.06
HIV negative or unknown 1st month 217 2 0.9 216 0.9 (0.2-3.7) 1.0
2nd month 215 2 1.8 213 0.9 (0.2-3.7) 1.01 (0.14-7.18)
3rd-6th month 213 4 3.7 844 0.5 (0.2-1.3) 0.51 (0.09-2.79)
7th-8th month 209 0 3.7 418 0.0 –
Overall 217 8 3.7 1691 0.5 (0.2-0.9)
<0.01
HIV positive on ART 1st month 277 14 5.1 270 5.2 (3.1-8.8) 1.0
2nd month 263 7 7.6 259 2.7 (1.3-5.7) 0.52 (0.21-1.29)
3rd-6th month 256 31 18.8 951 3.3 (2.3-4.6) 0.63 (0.33-1.18)
7th-8th month 225 9 22.0 439 2.1 (1.1-3.9) 0.39 (0.17-0.91)
Overall 277 61 22.0 1919 3.2 (2.5-4.1)
0.03
HIV positive not on ART 1st month 498 30 6.0 482 6.2 (4.4-8.9) 1.0
2nd month 468 19 9.8 461 4.1 (2.6-6.5) 0.66 (0.37-1.18)
3rd-6th month 449 66 23.1 1639 4.0 (3.2-5.1) 0.65 (0.42-1.00)
7th-8th month 383 17 26.5 744 2.3 (1.4-3.7) 0.37 (0.20-0.66)
Overall 498 132 26.5 3325 4.0 (3.3-4.7)
1Months 3–6 and 7–8 were grouped because mortality rates were observed to be stable during these time periods and the numbers of deaths were small.
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Figure 1 Kaplan-Meier curves showing survival time for first and retreatment TB episodes, by HIV status.
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Table 5 Risk factors for death stratified by time since starting TB treatment (includes first and retreatment episodes up to six months)
First Month Later months (2–6)
Category n Number
of deaths
Unadjusted
IRR (95% CI)
p-value Adjusted# p-value Number
of deaths
Unadjusted
IRR (95% CI)
p-value Adjusted# p-value
IRR (95% CI) IRR (95% CI)
Age at diagnosis* <35 years 524 8 1.0 0.06 1.0 0.17 27 1.0 <0.01 1.0 <0.01
35-44 years 1572 38 1.59 (0.74-3.41) 1.57 (0.73-3.37) 144 1.70 (1.12-2.59) 1.53 (1.01-2.33)
45-54 years 1731 58 2.19 (1.05-4.59) 1.92 (0.91-4.05) 182 1.98 (1.31-2.98) 1.77 (1.17-2.68)
>54 years 335 13 2.53 (1.05-6.10) 2.43 (1.00-5.88) 39 2.65 (1.65-4.27) 2.68 (1.66-4.33)
TB episode First 3170 71 1.0 <0.01 1.0 <0.01 237 1.0 <0.01 1.0 <0.01
> = 1 previous 992 46 2.10 (1.45-3.04) 2.20 (1.49-3.26) 155 1.63 (1.33-2.00) 1.46 (1.17-1.82)
HIV/ART status* Negative/unknown 1341 12 1.0 <0.01 1.0 <0.01 25 1.0 <0.01 1.0 <0.01
Positive: ART 652 29 5.06 (2.59-9.91) 3.17 (1.56-6.44) 77 6.37 (4.05-10.00) 6.02 (3.75-9.67)
Positive: no ART 2169 76 3.97 (2.16-7.29) 3.59 (1.94-6.66) 290 7.71 (5.13-11.61) 7.80 (5.15-11.80)
TB site Pulmonary 2393 77 1.0 0.02 1.0 <0.01 260 1.0 <0.01 1.0 <0.01
Extra-pulmonary 1535 30 0.60 (0.40-0.92) 0.54 (0.33-0.91) 115 0.69 (0.56-0.86) 0.57 (0.42-0.77)
No data 234 10 1.35 (0.70-2.60) 1.41 (0.69-2.88) 17 0.68 (0.42-1.12) 0.76 (0.46-1.27)
Year first diagnosed 1995-1998 742 9 1.0 <0.01 1.0 <0.01 58 1.0 <0.01 1.0 0.81
1999-2002 1177 24 1.69 (0.78-3.63) 1.81 (0.79-4.17) 129 1.47 (1.07-2.01) 1.18 (0.82-1.68)
2003-2005 1198 46 3.21 (1.57-6.55) 3.75 (1.63-8.61) 118 1.36 (0.99-1.87) 1.14 (0.77-1.69)
2006-2008 1043 38 3.05 (1.47-6.30) 3.97 (1.73-9.11) 87 1.18 (0.85-1.65) 1.14 (0.76-1.71)
Certainty of diagnosis Confirmed 1009 10 1.0 <0.01 1.0 <0.01 84 1.0 0.07 1.0 <0.01
Probable 1074 32 3.05 (1.50-6.20) 3.38 (1.65-6.93) 102 1.17 (0.88-1.56) 1.17 (0.87-1.58)
Possible 1120 56 5.15 (2.63-10.09) 6.28 (3.18-12.43) 134 1.56 (1.19-2.05) 1.73 (1.30-2.30)
No data 959 19 2.01 (0.94-4.33) 9.06 (3.82-21.51) 72 0.95 (0.70-1.31) 2.51 (1.64-3.85)
*time-varying covariates.
#Models were adjusted for all factors in the table.
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Figure 2 Kaplan-Meier curves showing survival time for TB episodes with microbiological data, by certainty of diagnosis.
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months of treatment, those with confirmed TB (positive
culture) were less likely to die than those with probable
TB (positive smear but negative or absent culture), and
those with possible TB (> = one negative smear or culture)
(log rank test p < 0.01).
Cardio-respiratory autopsy data were available for
121/228 (53%) of deaths occurring in men with con-
firmed or probable TB and 106/190 (56%) of deaths with
possible TB (Tables 6 and 7)). The proportion of deaths
for which autopsy was performed decreased from 94%
in 1997 to 39% in 2008 (p < 0.01), but men undergoing
autopsy were similar to those not autopsied according
to HIV prevalence (92% in autopsied and 94% in not
autopsied men (p = 0.6)) and age (mean 45.5 years in
autopsied and 44.9 years in men not autopsied men
(p = 0.2)). Clinical cause of death overestimated the pro-
portion of deaths attributable to TB in all groups, par-
ticularly in the latter stages of treatment in HIV positive
men. For example, among HIV positive men not on
ART in the later months of treatment, TB was recorded
as the clinical cause of death in 62% of deaths, whereas
only 26% of deaths could be attributed to TB at autopsy
(Table 6). Other infectious causes, often not identified
in life, accounted for many deaths at later time points
and in HIV positive men. Pneumonia, PCP, and other
infections were the leading causes among non-TB nat-
ural deaths. At autopsy, overall, only 35% of deaths
could be attributed to TB in men with confirmed,probable or possible TB dying within six months of start-
ing treatment (Tables 6 and 7).
Discussion
This study quantifies case fatality and mortality rates
by time from starting TB treatment within a large TB
programme in South Africa over fourteen years. The
strengths of this study lie in the large numbers, preci-
sion with which the occurrence and timing of deaths
were ascertained, and availability of cardiorespiratory
autopsy data. For the first time in the ART era, we
quantify the high risk of death during the first month
of TB treatment at a programme level, and emphasise
the risks associated with retreatment and HIV status.
Retreated men were more than twice as likely to die as
men undergoing a first TB episode, and HIV positive
men were over three times more likely to die than men
of negative or unknown HIV status. These data may in-
form projected estimates of mortality among co-infected
patients and corresponding lives saved [27].
In men undergoing treatment for a first TB episode,
the mortality rate in the first month after starting treat-
ment was highest amongst HIV positive patients receiv-
ing ART. We observed a sharp decline in mortality after
the first month in this group, although the mortality rate
over six months was comparable to those not receiving
ART. This may be due to patients at more advanced
stages of HIV infection and with lower immunity being
selected for ART, or a consequence of IRIS [28]. Other
Table 6 Clinical and autopsy cause of death by month since starting TB treatment for 228 deaths among men with
confirmed and probable TB1, by HIV status, n (%)
HIV negative or unknown HIV positive on ART HIV positive not on ART TOTAL
1st
month
2nd-6th
month
TOTAL 1st
month
2nd-6th
month
TOTAL 1st
month
2nd-6th
month
TOTAL
Clinical Cause of Death
TB 1 (50) 6 (75) 7 (70) 8 (100) 25 (66) 33 (72) 21 (66) 87 (62) 108 (63) 148 (65)
Non-TB natural deaths 1 (50) 2 (25) 3 (30) 0 13 (34) 13 (28) 11 (34) 52 (37) 63 (37) 79 (35)
Unnatural deaths 0 0 0 0 0 0 0 1 (1) 1 (1) 1 (0)
Autopsy Cause of Death
TB 1 (50) 2 (50) 3 (50) 3 (60) 6 (33) 9 (39) 11 (58) 19 (26) 30 (33) 42 (35)
Non-TB natural deaths 1 (50) 2 (50) 3 (50) 2 (40) 12 (67) 14 (61) 8 (42) 54 (73) 61 (66) 78 (64)
Pneumonia 2 2 5 7 1 19 20 29
Pneumocystis pneumonia 0 2 2 2 13 15 17
Cryptococcus 0 0 1 6 7 7
Other infection2 0 4 4 1 8 9 13
Kaposi’s sarcoma 0 0 1 1 1
Lung cancer 0 1 1 1 1 2 3
Other cancer 1 2 1 0 1 1 2 3
Other medical3 0 0 1 4 5 5
Unnatural deaths 0 0 1 (1) 1 (1) 1 (1)
No autopsy done 0 4 4 3 20 23 13 67 80 107
1228 men included 54 treated for the first time and 40 retreated with confirmed TB, and 75 treated for the first time and 59 retreated with probable TB (see
Table 1 footnote 1 for definitions used).
2Includes 12 men with HIV infection not otherwise specified and one with HIV infection and meningitis as the cause of death.
3Includes three men with stroke, one with diabetes, and one with silicosis as the cause of death.
Italics give numbers of deaths without percentages.
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term mortality in TB patients, with large reductions in
overall mortality in those receiving ART [29,30]. While
this population-based cohort study had excellent follow-
up information for the primary outcome of death, it did
not have detailed, individual-level clinical data, such as
CD4 counts, viral load, treatment regimens, adherence,Table 7 Clinical and autopsy cause of death by month since s
possible TB1, by HIV status, n (%)
HIV negative or unknown HIV positi
1st
month
2nd-6th
month
TOTAL 1st
month
Clinical Cause of Death
TB 3 (50) 1 (33) 4 (44) 10 (56)
Non-TB natural deaths 2 (33) 2 (67) 4 (44) 8 (44)
Unnatural deaths 1 (17) 0 1 (11) 0
Autopsy Cause of Death
TB 1 (33) 0 1 (25) 5 (36)
Non-TB natural deaths 1 (33) 1 (100) 1 (50) 9 (64)
Unnatural deaths 1 (33) 0 1 (25) 0
No autopsy done 3 2 5 4
1190 men included 118 treated for the first time and 72 retreated with possible TB
Italics give numbers of deaths without percentages.or interruptions, which would be needed to fully interpret
the impact of ART. This might be better ascertained
using prospective clinical cohorts, which collect such
data routinely.
Mortality rates declined with time after starting TB
treatment in all groups, with this effect most appreciable
in the HIV negative/unknown group. This is likely totarting TB treatment for 190 deaths among men with
ve on ART HIV positive not on ART TOTAL
2nd-6th
month
TOTAL 1st
month
2nd-6th
month
TOTAL
23 (61) 33 (59) 18 (56) 58 (62) 76 (61) 113 (59)
14 (37) 22 (39) 14 (44) 34 (37) 48 (38) 74 (39)
1 (3) 1 (2) 0 1 (1) 1 (1) 3 (2)
8 (44) 13 (41) 6 (35) 17 (32) 23 (33) 37 (35)
10 (56) 19 (59) 11 (65) 36 (68) 47 (67) 68 (64)
0 0 0 0 0 1 (1)
20 24 15 40 55 84
(see Table 1 footnote 1 for definitions used).
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Others have reported that most deaths in HIV positive
men undergoing TB treatment were from opportunistic
infections (mainly cryptococcus) and occurred later in
treatment [18,19]. Likewise, even amongst men with HIV
and confirmed or probable TB, we found at cardiorespira-
tory autopsy that TB was the cause of 58% of deaths in
the first month of treatment but only 27% of deaths in
later months. In this study, PCP and bacterial pneumonia
together accounted for over one third (46/121) of deaths
on the TB programme among men with confirmed or
probable TB. We know that other respiratory conditions
are often overlooked in TB patients [31-33], and that co-
trimoxazole prophylaxis substantially reduces mortality
from AIDS-related opportunistic infections in SSA set-
tings [34-36], and is recommended by South African TB
guidelines [25]. Although the HIV programme recom-
mended co-trimoxazole (960 mg daily) for all individuals
with a CD4 count of <250 cell/μl and isoniazid (300 mg
daily for 6 months) for all newly registered HIV patients,
prescribing data were not available for this study. To-
gether, these data also highlight the importance of aut-
opsies, not least to review clinical performance within a
TB programme [6,22].
Two other studies make comparisons between timing
of death for first episode and retreated TB [9,37]. In
Malawi, 41% of deaths during first TB episodes occurred
in the first month of treatment, compared to 29% for
retreatment, but monthly mortality rates were not pre-
sented [9]. In India, retreatment was associated with
higher mortality (relative risk = 1.93), but survival ana-
lysis indicated divergence in mortality between first and
retreatment episodes only after three months of treatment
[37]. In our study, although there was no difference in the
proportion of deaths occurring during the first month of
treatment for first and retreatment episodes (23% in both),
we observed a significant difference in early mortality
rates between the two groups (2.3/100 pm versus 4.7/
100 pm, adjusted IRR = 1.76), and our findings are consist-
ent with the overall higher mortality in retreated cases
found in other TB programmes [17,37]. Recurrent TB is
common among HIV positive patients in SSA, and can be
due to treatment failure, drug resistance, or reinfection.
Recurrence may be diagnosed earlier by improved follow-
up for patients completing TB treatment, and reduced by
isoniazid prophylaxis and ART [38].
In all patient groups, misdiagnosis is a serious concern.
Throughout SSA many deaths occur in patients mis-
takenly treated for TB [13,20,21,33,39,40]. In this TB
programme, among those with confirmed or probable TB,
only 50% (3/6) of deaths at autopsy in men not known to
have HIV and 34% (39/115) in HIV positive men could be
attributed to TB, whereas clinicians attributed the cause
of death to TB in 70% (7/10) and 65% (141/217) of deathsrespectively. Even in the first month of treatment among
men with confirmed or probable TB, only 58% (15/26) of
deaths were attributable to TB at autopsy. Linked to this,
and supporting previous findings [39], we found that
mortality was strongly associated with diagnostic cer-
tainty, although we acknowledge that diagnosis might
be complicated by HIV infection and the increased mor-
tality found in “possible” TB cases might be attributable
to smear-negative or extrapulmonary TB as well to
other undiagnosed infections. It is likely that many men
in this programme were inappropriately diagnosed and
treated for TB from the outset, indicating preventable
deaths and the importance of performing proper diag-
nostic tests for TB [40].
This study is strengthened by statistical comparisons
of incident mortality, presented in conjunction with case
fatality, which assists inter-study comparisons because
most studies present one but not both statistics. The
study benefits from detailed company records showing
treatment outcomes for a large cohort but, for this rea-
son, includes only men employed at a platinum mine,
which may limit generalisability. Unlike goldminers, who
have an increased risk of TB due to silica dust exposure,
silicosis is not common in platinum miners, so the find-
ings are relevant to other hospital or occupational cohorts
[41,42]. The study is also strengthened by the availability
of cardio-respiratory autopsy data in many patients. The
autopsy data are likely to be representative of all deaths in
the programme, since the decision to conduct an autopsy
was independent of the clinical cause of death. Although
rich in mortality and autopsy data, the study is limited by
a lack of clinical data, which might provide further insight
into some findings. For example, information about TB
drug resistance and HIV disease progression was not
available, and some data were missing, including dates of
HIV testing and HIV negative tests, smear and culture
data prior to 2000, and the site of TB infection. We
recoded the HIV status of some men based on their cause
of death, which may introduce a bias, but we did so to
avoid overestimating the mortality in men otherwise
thought to be HIV negative. We note that the South
African guidelines on regimens for retreatment of TB
and ART eligibility changed after the end of the study
period. Finally, this study does not include undiagnosed
TB cases and there may be many TB deaths occurring
outside of the programme, which we have previously
shown to be an issue [21].
Conclusions
We found high mortality in the first month after starting
TB treatment in all patient groups, and we have used
autopsy data to document the high frequency of non-TB
deaths in a large TB programme. TB prevention and
earlier accurate diagnosis, recognition of the role of HIV
Field et al. BMC Infectious Diseases  (2014) 14:3858 Page 11 of 12and shorter pathways to TB treatment initiation may
reduce death rates. These findings suggest that resources
should continue to be targeted to improve diagnostic
accuracy and ensure effective clinical care in the early
stages of TB treatment.
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